Revenue growth has accelerated to 137.7% in 2026Q1, supported by high gross margins that reached 87.1% despite significant R&D expenditures exceeding $79.8 million per quarter.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Sales/Revenue | 66.05M | 54.03M | 36.5M | 26.82M | 14.24M | 0 | 0 | 117.91M | 94.39M | 43.01M | 69.89M | 59.12M | 65.36M | 25.55M | 25.11M | 21.84M |
| Revenue Growth % | 78.34% | 48.03% | 36.07% | 88.36% | - | - | -100% | 24.92% | 119.45% | -38.46% | 18.22% | -9.55% | 155.82% | 1.76% | 14.97% | - |
| Cost of Goods Sold | 11.84M | 11.52M | 4.17M | 9.5M | 1.7M | 18.78M | 18.77M | 1.32M | 1.4M | 292.68M | 220.16M | 141.83M | 100.37M | 54.5M | 41.04M | 0 |
| COGS % of Revenue | - | 21.33% | 11.41% | 35.43% | 11.97% | - | - | 1.12% | 1.48% | 680.48% | 315% | 239.9% | 153.57% | 213.33% | 163.45% | - |
| Gross Profit | 54.21M | 42.51M | 32.33M | 17.32M | 12.54M | -18.78M | -18.77M | 116.59M | 92.99M | -249.67M | -150.27M | -82.71M | -35.01M | -28.95M | -15.93M | 21.84M |
| Gross Margin % | 82.07% | 78.67% | 88.59% | 64.57% | 88.03% | - | - | 98.88% | 98.52% | -580.48% | -215% | -139.9% | -53.57% | -113.33% | -63.45% | 100% |
| Gross Profit Growth % | - | 31.46% | 86.69% | 38.15% | 166.76% | -0.03% | -116.1% | 25.38% | 137.25% | -66.15% | -81.69% | -136.22% | -20.93% | -81.75% | -172.95% | - |
| Operating Expenses | 529.74M | 514.64M | 458.07M | 408.81M | 401.58M | 359.64M | 317.14M | 542.93M | 455.47M | 363.81M | 270.88M | 177.82M | 119.49M | 64.43M | 48.1M | 38.47M |
| OpEx % of Revenue | - | 952.54% | 1255.06% | 1524.09% | 2820.11% | - | - | 460.45% | 482.55% | 845.84% | 387.57% | 300.78% | 182.83% | 252.2% | 191.59% | 176.16% |
| Selling, General & Admin | 187.06M | 180.28M | 156.78M | 119.9M | 121.67M | 121.44M | 106.12M | 132.03M | 114.14M | 71.12M | 50.71M | 35.99M | 19.12M | 9.93M | 7.06M | 7.21M |
| SG&A % of Revenue | - | 333.68% | 429.57% | 447.02% | 854.45% | - | - | 111.98% | 120.93% | 165.36% | 72.56% | 60.88% | 29.25% | 38.86% | 28.14% | 33.04% |
| Research & Development | 342.68M | 334.36M | 301.29M | 288.9M | 279.91M | 256.97M | 211.02M | 410.89M | 341.32M | 292.68M | 220.16M | 141.83M | 100.37M | 54.5M | 41.04M | 31.25M |
| R&D % of Revenue | - | 618.86% | 825.49% | 1077.07% | 1965.66% | - | - | 348.48% | 361.62% | 680.48% | 315% | 239.9% | 153.57% | 213.33% | 163.45% | 143.12% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -18.78M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -475.53M | -472.13M | -425.74M | -391.49M | -389.05M | -378.42M | -335.92M | -426.33M | -362.48M | -320.79M | -200.99M | -118.7M | -54.13M | -38.88M | -23M | -16.63M |
| Operating Margin % | -719.97% | -873.87% | -1166.47% | -1459.52% | -2732.07% | - | - | -361.57% | -384.03% | -745.84% | -287.57% | -200.78% | -82.83% | -152.2% | -91.59% | -76.16% |
| Operating Income Growth % | - | -10.9% | -8.75% | -0.63% | -2.81% | -12.65% | 21.21% | -17.62% | -12.99% | -59.61% | -69.32% | -119.27% | -39.22% | -69.09% | -38.27% | - |
| EBITDA | -470.27M | -466.95M | -420.08M | -384.86M | -380.48M | -359.64M | -317.14M | -409.71M | -355.31M | -314.36M | -195.28M | -115.36M | -52.77M | -37.44M | -21.82M | -15.83M |
| EBITDA Margin % | -712.01% | -864.28% | -1150.98% | -1434.83% | -2671.93% | - | - | -347.47% | -376.44% | -730.89% | -279.4% | -195.13% | -80.73% | -146.56% | -86.9% | -72.49% |
| EBITDA Growth % | -8.18% | -11.16% | -9.15% | -1.15% | -5.8% | -13.4% | 22.59% | -15.31% | -13.02% | -60.98% | -69.28% | -118.62% | -40.92% | -71.63% | -37.81% | - |
| D&A (Non-Cash Add-back) | 5.26M | 5.18M | 5.65M | 6.62M | 8.56M | 18.78M | 18.77M | 16.62M | 7.17M | 6.43M | 5.71M | 3.34M | 1.37M | 1.44M | 1.18M | 801K |
| EBIT | -475.53M | -472.13M | -425.74M | -391.49M | -389.05M | -356.51M | -329.31M | -411.47M | -346.03M | -320.79M | -200.99M | -118.7M | -54.13M | -38.88M | -23M | -16.63M |
| Net Interest Income | 51.09M | 56.38M | 48.08M | 33.34M | 12.79M | 836K | -11.22M | 14.86M | 16.45M | 6.12M | 2.51M | 968K | 203K | 55K | 69K | 132K |
| Interest Income | 51.09M | 56.38M | 48.08M | 33.34M | 12.79M | 836K | 6.61M | 14.86M | 16.45M | 6.12M | 2.51M | 968K | 203K | 55K | 69K | 132K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 17.83M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 51.91M | 58.34M | 1.14B | 39.4M | 157.25M | 21.91M | 6.61M | 14.86M | 16.45M | 6.12M | 2.51M | 968K | 203K | 55K | 69K | 132K |
| Pretax Income | -423.62M | -413.8M | 717.97M | -352.09M | -231.8M | -356.51M | -329.31M | -411.47M | -346.03M | -314.67M | -198.47M | -117.73M | -53.93M | -38.83M | -22.93M | -16.5M |
| Pretax Margin % | -641.38% | -765.89% | 1967.15% | -1312.63% | -1627.82% | - | - | -348.97% | -366.61% | -731.6% | -283.97% | -199.14% | -82.51% | -151.98% | -91.32% | -75.56% |
| Income Tax | -1.02M | -1.02M | 44.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -426K | -426K | 579K | -2.82M | 7.21M |
| Effective Tax Rate % | 0.24% | 0.25% | 6.16% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.36% | 0.79% | -1.49% | 12.32% | -43.68% |
| Net Income | -422.6M | -412.78M | 673.73M | -352.09M | -231.8M | 1.6B | -327.37M | -411.47M | -346.03M | -314.67M | -198.47M | -117.73M | -53.5M | -39.41M | -20.1M | -23.71M |
| Net Margin % | -639.84% | -764.01% | 1845.92% | -1312.63% | -1627.82% | - | - | -348.97% | -366.61% | -731.6% | -283.97% | -199.14% | -81.86% | -154.25% | -80.07% | -108.56% |
| Net Income Growth % | -163.46% | -161.27% | 291.35% | -51.89% | -114.44% | 590.18% | 20.44% | -18.91% | -9.97% | -58.55% | -68.58% | -120.04% | -35.77% | -96.04% | 15.2% | - |
| Net Income (Continuing) | -422.6M | -412.78M | 673.73M | -352.09M | -231.8M | -356.51M | -329.31M | -411.47M | -346.03M | -314.67M | -198.47M | -117.73M | -53.5M | -39.41M | -20.1M | -23.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 1.96B | 1.94M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -7.19 | -7.12 | 11.64 | -6.33 | -4.23 | -6.36 | -4.74 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 | -2.56 | -0.86 | -1.01 |
| EPS Growth % | -164.22% | -161.17% | 283.89% | -49.65% | 33.49% | -34.18% | 28.29% | -9.62% | 10.67% | -33.14% | -60.95% | -98.11% | 37.89% | -197.67% | 14.85% | - |
| EPS (Basic) | - | -7.12 | 11.86 | -6.33 | -4.23 | -6.36 | -4.74 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 | -2.56 | -0.86 | -1.01 |
| Diluted Shares Outstanding | 58.78M | 57.97M | 57.89M | 55.65M | 54.79M | 60.45M | 69M | 59.99M | 57.42M | 46.59M | 39.13M | 37.43M | 33.67M | 15.41M | 23.39M | 23.39M |
| Basic Shares Outstanding | 58.78M | 57.97M | 56.81M | 55.65M | 54.79M | 60.45M | 69M | 59.99M | 57.42M | 46.59M | 39.13M | 37.43M | 33.67M | 15.41M | 23.39M | 23.39M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
High Cash Burn Rate
According to recent quarterly financial statements, AGIO has demonstrated a significant revenue acceleration, with year-over-year growth reaching 137.7% in 2026Q1, signaling that the commercial rollout of PYRUKYND is gaining meaningful traction within the rare disease market despite the company's relatively small absolute revenue base.
The sharp uptick in top-line performance suggests that the company is successfully navigating the difficult patient identification phase for PK deficiency. Investors should monitor whether this growth trajectory is sustainable or if it reflects a temporary surge in early-adopter enrollment that may plateau as the addressable population is saturated.
As reported in financial filings, AGIO maintains robust gross margins consistently above 75%, peaking at 87.1% in 2026Q1, which underscores the inherent pricing power of its orphan drug portfolio and the relatively low variable costs associated with its small-molecule therapeutic manufacturing process.
While these gross margins are impressive, they appear insufficient to offset the heavy R&D and SG&A burden required to support the company's clinical pipeline and commercial infrastructure. This structural disparity suggests that the company remains far from achieving the operating leverage necessary to reach a break-even point on a GAAP basis.
Based on the provided income statement data, AGIO's R&D expenditures consistently exceed $70M per quarter, often dwarfing total revenue, which indicates that the company is prioritizing long-term pipeline development over near-term profitability in its pursuit of broader label expansions for its metabolic platform.
The persistence of these high R&D costs suggests that management is heavily invested in the ENERGIZE trials to unlock larger market opportunities. Investors should consider whether this level of spending is disciplined or if it reflects an inability to streamline clinical operations as the company matures.
Analysis of the reported figures reveals a persistent operating loss exceeding $100M per quarter, which, when contrasted with the reported cash position of $89.13M, suggests a precarious financial runway that warrants immediate investigation into potential liquidity risks or undisclosed capital sources.
The disconnect between the company's high-growth narrative and its rapid cash depletion may indicate that the current commercial model is not yet self-sustaining. Market participants should be wary of the potential for dilutive financing events if the company cannot demonstrate a clear path to narrowing its operating losses in the coming quarters.
Quick answers to the most common questions about buying AGIO stock.
For fiscal year 2025, Agios Pharmaceuticals, Inc. (AGIO) reported total revenue of $54.0M. This represents a 147.4% increase compared to $21.8M in 2011.
Agios Pharmaceuticals, Inc. (AGIO) reported a net loss of $412.8M for the fiscal year ending 2025.
Agios Pharmaceuticals, Inc. (AGIO) reported an operating income of $-472.1M, resulting in an operating profit margin of -873.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Agios Pharmaceuticals, Inc. (AGIO) generated $42.5M in gross profit for the year, representing a gross profit margin of 78.7%. This demonstrates the company's core pricing power and production efficiency.